Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02782039
  4. Details
NCT02782039 Clinical Trial

Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus (SLE) Clinical Trial

— SAPL-LUPUS  

Official title:
Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02782039
Other study ID # NI15010
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 17, 2017
Est. completion date May 2022

Study information
Verified date July 2021
Source Assistance Publique - Hôpitaux de Paris
Contact Nathalie Costedoat-Chalumeau, MD, PhD
Phone +33 1 58 41 32 41
Email nathalie.costedoat@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of that register is to collect medical information about patients suffering of APS with or without associated SLE.

Description:

Recruitment of patients with APS and SLE treated. Retrospective and prospective register.

Recruitment information / eligibility
Status Recruiting
Enrollment 300
Est. completion date May 2022
Est. primary completion date November 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with APS - Patient with SLE Exclusion Criteria: - Dependent person - Hospitalized without consent and not protected by law - Detainee

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Hôpital Claude Huriez Lille
France Hôpital Cochin Paris

Sponsors (1)
Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of patients enrolled with Anti-Phospholipids syndrome (APS) and/or Systemic Lupus Erythematosus (SLE) 5 years
See also
  Status Clinical Trial Phase
Completed NCT04461158 - CCCR Lupus Patient Navigator Program N/A
Completed NCT02006784 - Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE) N/A
Completed NCT01072734 - Auto-immunity in Lupus Patients After Influenza Vaccine Phase 2
Completed NCT03626311 - Omega-3 Replacement With Krill Oil in Disease Management of SLE N/A
Withdrawn NCT02779153 - Acthar SLE (Systemic Lupus Erythematosus) Phase 4
Completed NCT01992666 - GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus N/A
Completed NCT00779194 - Prospective Study of Rapamycin for the Treatment of SLE Phase 2
Recruiting NCT00582881 - Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
Terminated NCT02811094 - LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse N/A
Recruiting NCT05458622 - 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol Phase 3
Recruiting NCT06144710 - SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus Phase 1
Completed NCT03031925 - Detection of Annexin A2 in Systemic Lupus Erythematosus N/A
Recruiting NCT05859997 - Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases N/A
Recruiting NCT05567198 - Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
Recruiting NCT05747651 - 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
Recruiting NCT03030976 - A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) Phase 1
Recruiting NCT06249438 - A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy Phase 1
Not yet recruiting NCT05724940 - Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus
Recruiting NCT06032923 - Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus Phase 1/Phase 2
Completed NCT03122431 - Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Phase 4